Nursing School, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China.
PLoS One. 2023 Aug 11;18(8):e0290085. doi: 10.1371/journal.pone.0290085. eCollection 2023.
Systematic evaluation of the improvement effect of non-pharmacological intervention on patients with sarcopenic obesity.
Wanfang, VIP, China National Knowledge Infrastructure (CNKI), SinoMed, Web of Science, Cochrane Library, PubMed, and Embase databases were searched systematically for randomized controlled trials (RCTS) and experimental studies of non-pharmacological interventions on patients with sarcopenic obesity. The retrieval period was from the establishment of the databases to October 31, 2022. Meta-analysis was conducted using RevMan 5.4.
A total of 18 studies involving 1,109 patients were included. Meta-analysis results showed that non-pharmacological interventions improved patients' body weight [mean difference, MD = -2.74, 95% CI (-4.79, -0.70), P = 0.009], body fat percentage [MD = -0.67, 95% CI (-0.96, -0.38), P<0.00001], grip strength [MD = 1.29, 95% CI (0.81, 1.77), P<0.00001], gait speed [MD = 0.05, 95% CI (0.03, 0.07), P<0.00001], and knee extension strength [MD = 2.56, 95% CI (1.30, 3.82), P<0.0001].
Non-pharmacological interventions can effectively improve the clinical symptoms and signs of patients with sarcopenic obesity. Dissemination of this information will be therapeutically useful.
Registration. The PROSPERO No. is CRD42023403341.
系统评价非药物干预对肌少症合并肥胖患者的改善效果。
系统检索万方、维普、中国知网、中国生物医学文献服务系统、Web of Science、Cochrane 图书馆、PubMed 和 Embase 数据库，收集关于非药物干预肌少症合并肥胖患者的随机对照试验（RCT）和实验研究。检索时限为各数据库建库至 2022 年 10 月 31 日。采用 RevMan 5.4 软件进行 Meta 分析。
共纳入 18 项研究，涉及 1109 例患者。Meta 分析结果显示，非药物干预可改善患者的体重[均数差（MD）=-2.74，95%置信区间（CI）（-4.79，-0.70），P=0.009]、体脂百分比[MD=-0.67，95%CI（-0.96，-0.38），P<0.00001]、握力[MD=1.29，95%CI（0.81，1.77），P<0.00001]、步速[MD=0.05，95%CI（0.03，0.07），P<0.00001]和膝关节伸展力量[MD=2.56，95%CI（1.30，3.82），P<0.0001]。
非药物干预可有效改善肌少症合并肥胖患者的临床症状和体征。传播这些信息将具有治疗意义。
注册。PROSPERO 编号：CRD42023403341。
